Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
Trial details
- Registry ID
- NCT04655313
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Topical roflumilast
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)NCT04655313 | ARQT | Phase 2 | Completed | 2022-01-12Actual |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)NCT04746911 | ARQT | Phase 2 | Completed | 2022-05-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |